A PHASE III, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL STUDY OF LCI699 FOLLOWING A 24 WEEK, SINGLE-ARM, OPEN-LABEL DOSE TITRATION AND TREATMENT PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF LCI699 FOR THE TREATMENT OF PATIENTS WITH CUSHING'S DISEASE
- Registry ID
- CLCI699C2301
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2018-11-13
- Completion date
- 2020-09-04
- Last update
- 2014-07-03
Conditions
View on source registry